Hypoglycemia and insulin analogues: Is there a reduction in the incidence?

Journal of Diabetes and its Complications

Volumn 13, Issue 2, 1999, Pages 105-114

  Heinemann, Lutz ^a  

^a Dept of Metab Dis and Nutrition   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INSULIN DERIVATIVE; INSULIN LISPRO;

CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOSE TIME EFFECT RELATION; FOOD INTAKE; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN TREATMENT; METABOLIC REGULATION; PRIORITY JOURNAL; REVIEW;

BLOOD GLUCOSE; COHORT STUDIES; CROSS-OVER STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; META-ANALYSIS; TIME FACTORS;

EID: 0033038223     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8727(99)00031-8     Document Type: Review

References (53)

1. Heinemann L., Breuer J., Cebulla D., Wüssel B., Bender R., Heise T. Wirkungsprofile von Normalinsulin, NPH-Insulin sowie einer 25/75-Mischung hergestellt aus gentechnologischem bzw. semisynthetischem Humaninsulin. Diabetes u Stoffw. 5:1996;157-163.
2. Berger M. Towards more physiological insulin therapy in the 1990s. A comment. Diabetes Res Clin Pract. 6:1989;S25-S31.
3. Vora J.P., Owens D.R., Dolbern J., Atiea J.A., Dean J.D., Kang S., Burch A., Brauge J. Recombinant DNA derived monomeric insulin analogue. comparison with soluble human insulin in normal subjects BMJ. 297:1988;1236-1239.
4. Brange J., Owens D.R., Kang S., Volund A. Monomeric insulins and their experimental and clinical implications. Diabetes Care. 13:1990;923-954.
5. Kang S., Owens D.R., Vora J.P., Brange J. Comparison of insulin analogue B9AspB27Glu and soluble human insulin in insulin-treated diabetes. Lancet. 335:1990;303-306.
6. Kang S., Brange J., Burch A., Volund A., Owens D.R. Absorption kinetics and action profiles of subcutaneously administered insulin analogues (AspB9GluB27, AspB10,AspB28) in healthy subjects. Diabetes Care. 14:1991;1057-1065.
7. Heinemann L., Starke A.A.R., Heding L., Jensen I., Berger M. Action profiles of fast onset insulin analogues. Diabetologia. 33:1990;384-386.
8. Heinemann L., Heise T., Jorgensen L.N., Starke A.A.R. Action profile of the rapid-acting insulin analogue B28Asp. Diabetic Med. 10:1993;535-539.
9. Howey D.C., Bowsher R.R., Brunelle R.L., Woodworth J.R. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes. 43:1994;396-402.
10. Woodworth J.R., Howey D.C., Bowsher R.R., Lutz S., Sante P.F., Brandy P. [Lys(B28), Pro (B29)] human insulin (K). Dose-ranging vs. humulin R (H) Diabetes. 42(suppl 1):1993;54A.
11. Barnett A.H., Owens D.R. Insulin analogues. Lancet. 349:1997;47-51.
12. Berger M., Heinemann L. Are presently available insulin analogues clinically beneficial? Diabetologia. 40(suppl 2):1997;S91-S96.
13. MacLeod K.M., Hepburn O.H., Frier B.M. Frequency and morbidity of severe hypoglycaemia in insulin-treated diabetic patients. Diabetic Med. 10:1993;238-245.
14. Wredling R.A.M., Tôtes Theorell P.G., Roll H.M., Lines P.E.S., Adamson K.K.C. Psychosocial state of patients with IDDM prone to recurrent episodes of severe hypoglycaemia. Diabetes Care. 15:1992;518-521.
15. Pramming S., Thorsteinsson B., Bendtson I., Binder C. The relationship between symptomatic and biochemical hypoglycaemia in insulin-dependent diabetic patients. J Intern Med. 228:1990;641-646.
16. Pieber T.R., Feinbock C., Rabenstiener D., Weitgasser R., Ristic C. Lispro insulin analogue twice-a-day insulin treatment. Diabetologia. 38(suppl 1):1995;A3.
17. Pfützner A., Küstner E., Forst T., Schutze-Schleippinghoff B., Trautmann M.E., Haslbeck M., Schatz H., Beyer J., on behalf of the German insulin Lispro/IDDM study group Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycaemic episodes. Exp Clin Endocrinol Diabetes. 104:1996;25-30.
18. Garg S.K., Carmain J.A., Braddy K.C., Anderson J.H., Viganti L., Jennings M.K., Chase H.P. Pre- meal insulin analogue insulin lispro vs. Humulin R insulin treatment in young subjects with type 1 diabetes. Diabetic Med. 13:1996;47-52.
19. Pfützner A., Gudat U., Trautman M.E., Holcombe J. Use of insulin lispro in pediatric patients with IDDM. Diabetologica. 39(suppl 1):1996;A222.
20. Anderson J.H., Brunelle R.L., Koivisto V.A., Pfützner A., Trautmann M.E., Vignati L., DiMarchi R., the Multicenter Insulin Lispro Study Group Reduction of postprandial hyperglycemia and frequency of hypoglycaemia in IDDM patients on insulin-analog treatment. Diabetes. 46:1997;265-270.
21. Anderson J.H., Brunelle R.L., Koivisto V., Trautmann M.E., Vignati L., DiMarchi R. Improved mealtime treatment of diabetes mellitus using insulin analogue. Clin Ther. 19:1997;62-72.
22. Anderson J.H., Brunelle R.L., Keohane P., Koivisto V.A., Trautmann M.E., Vignati L., DiMarchi R. Mealtime treatment with insulin analogue improves postprandial hyperglycemia and hypoglycemia in NIDDM patients. Arch Intern Med. 157:1997;1249-1255.
23. Jacobs M.A., Kenton E.L., Kanc K., Casteleigh S., Schaffer P., Deville W., Heine R.J. Metabolic efficacy of preprandial administration of Lys(B28), Pro(B29) human insulin analog in IDDM patients. Diabetes Care. 20:1997;1279-1286.
24. Holleman F., Schmitt H., Rottiers R., Rees A., Symanowski S.M., Anderson J.H., The Benelux-UK Insulin Lispro Study Group Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. Diabetes Care. 20:1997;1827-1832.
25. Holcombe J.H., Zalani S., Arora A., Headlee S., Gill A. Insulin lispro (LP) results in less nocturnal hypoglycaemia compared with regular human insulin in adolescents with type 1 diabetes. Diabetes. 46(suppl 1):1997;103A.
26. Holcombe J.H., Zalani S., Arora V., Headlee S., Gill A. Comparative study of insulin lispro and regular insulin in 481 adolescents with type 1 diabetes. Diabetes. 46(suppl 1):1997;329A.
27. Heller S.R., Amiel S., Janes J. Hypoglycaemia during intensive insulin therapy; a comparison of lispro and regular insulin. Diabetes. 46(suppl 1):1997;151A.
28. Jansson P., Ebling P., Smith U., Conget I., Coves M., Gomis R., Lallil C., Bolli G., Koivisto V. Glycemic control in IDDM is improved by optimized combination of insulin lispro and basal insulin. Diabetes. 46(suppl 1):1997;162A.
29. Sindaco P., Ciofetta M., Torlone E., Perriello G., Brunetti P., Bolli G. Importance of basal insulin in intensive treatment of IDDM with lispro insulin. Diabetes. 46(suppl 1):1997;331A.
30. Ross S., Zinman B., Campos R., Strack T., The Canadian Lispro Study Group Effectiveness and safety of lispro in the management of patients with type II diabetes. Diabetes. 46(suppl 1):1997;329A.
31. Rönnemaa T., Viikari J. Reduction of snacks when switching IDDM patients from regular insulin to lispro insulin. Diabetologia. 40(suppl 1):1997;A350.
32. Rowe R., Anderson J.H., Gale E. A double-blind comparison of insulin lispro and regular insulin in patients on a multiple injection regimen. Diabetes. 45(suppl 2):1996;71A.
33. Pfützner A., Renner R., The German Humalog CSII Study Group CSII therapy with insulin pumps using insulin lispro. Diabetes. 46(suppl 1):1997;34A.
34. Bode B., Steed R., Davidson P. Continuous subcutaneous insulin infusion (CSII). A study comparing lispro to regular human insulin. Diabetes. 46(suppl 1):1997;43A.
35. 1c and blood glucose stability under insulin lispro Diabetes. 46(suppl 1):1997;157A.
36. Tsui E., Chiasson J.L., Tildesley H., Barnie A., Simkins S., Strack T., Zinman B. Counterregulatory hormone responses after long-term continuous subcutaneous insulin infusion with lispro insulin. Diabetes Care. 21:1998;93-96.
37. Schmauß S., König A., Landgraf R. Human insulin analogue [LYS(B28), PRO(B29)]. The ideal pump insulin? Diabetic Med. 15:1998;247-249.
38. Zinman B., Tildesly H., Chiasson J.L., Tsui E., Strack T. Insulin lispro in CSII. Results of a double-blind cross-over study Diabetes. 46:1997;440-443.
39. Nielsen F.S., Jorgensen L.N., Ipsen M., Vooldsgaad A.I., Parving H.H. Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen. Diabetologia. 38:1995;592-598.
40. Round P., Olsen K.J., Home P.D., for the B28-Asp UK study group Improved blood glucose control with insulin analogue B28Asp. Diabetologia. 39(Suppl.1):1996;A24.
41. The Diabetes Control and Complications Trial research group The absence of a glycemic threshold for the development of long term complications. The perspective of the diabetes control and complications trial Diabetes. 45:1996;1289-1298.
42. Bott S., Bott U., Berger M., Mühlhauser I. Intensified insulin therapy and the risk of severe hypoglycaemia. Diabetologia. 40:1997;926-932.
43. Jörgens V., Grusser M., Bott U., Mühlhauser I., Berger M. Effective and safe translation of intensified insulin therapy to general internal medicine departments. Diabetologia. 36:1993;99-105.
44. Brunelle Rl Trautmann M.E., Koivisto V., Vignati L. Improved glucose control with insulin lispro demonstrated by reducing glucose variability. Diabetologia. 40(suppl 1):1997;A350.
45. Brunelle R.L., Llewelyn J., Vignati L., Anderson J.H., Koivosto V. Humalog reduces the incidences of severe hypoglycaemia in IDDM patients. Diabetologia. 40(suppl 1):1997;A352.
46. Davey P., Grainger D., MacMillan J., Rajan N., Aristides M., Gliksman M. Clinical outcome with insulin lispro compared with human regular insulin. A meta-analysis Clin Ther. 19:1997;656-674.
47. Ahmed M., Home P.D. The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients. Diabetes Care. 21:1998;32-37.
48. Burge M.R., Castillo K.R., Schade D.S. Meal composition is a determinant of lispro-induced hypoglycaemia in IDDM. Diabetes Care. 20:1997;152-165.
49. Strachan M.W., Frier B.M. Early postprandial hypoglycemia following administration of lispro insulin. Diabetes Care. 20:1997;1214-1215.
50. Tuominen J.A., Karonen Sl Melamies L., Bolll G., Koivisto V.A. Exercise-induced hypoglycaemia in IDDM patients treated with a short-acting insulin analogue. Diabetologia. 38:1995;106-111.
51. Jacobs M.A., Salobir B., Popp-Snijders C., Ader H., Heine R.J. Counterregulatory hormone responses and symptoms during hypoglycaemia induced by porcine, human regular insulin, and Lys(B28), Pro(B29) human insulin analogue (insulin lispro) in healthy male volunteers. Diabetic Med. 14:1997;248-257.
52. McCrimmon R.J., Frier B.M. Symptomatic and physiological responses to hypoglycaemia induced by human soluble insulin and the analogue lispro human insulin. Diabetic Med. 14:1997;929-936.
53. Torlone E., Fanelli C., Rambotti A.M., Kassi G., Modarelli F., Di Vincenzo A., Epifano L., Ciofetta M., Pampanelli S., Brunetti P., Bolli G.B. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [lys(B28,pro(B29)] in IDDM. Diabetologia. 37:1994;713-720.